ProSciento Presents Diabetes, Obesity and NASH Research Study Results at the European Association for the Study of Diabetes Annual Meeting

ProSciento Presents Diabetes, Obesity and NASH Research Study Results at the European Association for the Study of Diabetes Annual Meeting

SAN DIEGO, September 10, 2015 – ProSciento Inc., an clinical research organization (CRO) focused on diabetes, obesity and NAFLD/NASH, and sponsors will present prominent study results at next week’s European Association for the Study of Diabetes (EASD) 51th Annual Meeting, September 14-18 in Stockholm, Sweden.

Poster presentations co-authored by ProSciento scientists include:
Significant effects of HM11260C on body weight over 20 weeks in obese subjects without diabetes: a randomized, double-blind, placebo controlled study || Abstract #643
Tuesday, September 15, 2015, 13:45 – 14:45, Poster Hall
PS 050 GLP-1 based therapies for obesity

A single dose study in healthy subjects demonstrating pharmacokinetic and pharmacodynamic equivalence between MK-1293 and EU- and US-approved innovator insulin glargine || Abstract #966
Tuesday, September 15, 2015, 12:30 – 13:30, Poster Hall
PS 091 Basal insulin therapy

Superagonistic mechanism of increased glucodynamic and weight loss effects of LAPSCA-Exendin-4 (efpenglenatide) || Abstract #788
Wednesday, September 16, 2015, 12:30 – 13:30, Poster Hall
PS 069 GLP-1 receptor agonists: approaching approvability

Potent weight loss mechanism and effect on NASH of the novel long-acting GLP-1/Glucagon dual receptor agonist (HM12525A) || Abstract #790
Wednesday, September 16, 2015, 12:30 – 13:30, Poster Hall
PS 069 GLP-1 receptor agonists: approaching approvability

The ultra-long acting LAPSGLP/GCG dual agonist, HM12525A, demonstrated safety and prolonged pharmacokinetics in healthy volunteers: a phase 1 first-in-human study || Abstract #791
Wednesday, September 16, 2015, 12:30 – 13:30, Poster Hall
PS 069 GLP-1 receptor agonists: approaching approvability

LAPSExendin-4 (HM11260C) enhances insulin secretion and beta cell responsiveness in subjects with type 2 diabetes || Abstract #792
Wednesday, September 16, 2015, 12:30 – 13:30, Poster Hall
PS 069 GLP-1 receptor agonists: approaching approvability

Dose-response improvements in glycaemic control and body weight reduction with HM11260C, a once weekly GLP-1 receptor agonist with liraglutide as reference, in type 2 diabetes || Abstract #793
Wednesday, September 16, 2015, 12:30 – 13:30, Poster Hall
PS 069 GLP-1 receptor agonists: approaching approvability

A novel once weekly combination of long-acting GLP-1R agonist and insulin analog (HM14220) offers favorable PK/PD and mitogenic properties || Abstract #935
Wednesday, September 16, 2015, 12:30 – 13:30, Poster Hall
PS 087 New and emerging insulin therapies

Oral presentations include:
BIOD-531 demonstrates superior prandial glucose control, post-meal dosing flexibility, and less insulin “stacking” compared to marketed prandial/basal insulins || Abstract #6
Tuesday, September 15, 2015, 12:00 – 12:15, Hellerström Hall
OP 01 Insulin analogues: Is newer always better?

Unique profile of the weekly insulin HM12470: Very slow onset of action, rapid off-rate similar to insulin, and absence of insulin receptor downregulation || Abstract #41
Tuesday, September 15, 2015, 16:00 – 16:15, Hellerström Hall
OP 07 A glimpse at future diabetes therapy

Once a month treatment with HM11260C improves glycaemic control in type 2 diabetes mellitus: interim data from a 16-week study || Abstract #113
Wednesday, September 16, 2015, 17:00 – 17:15, Hellerström Hall
OP 19 incretin-based therapy: novel agents, new indications

Poster session chaired by ProSciento’s Dr. Marcus Hompesch:
PS 051 Obesity: emerging concepts in aetiopathogenesis
Wednesday, September 16, 2015, 12:30 – 13:30, Poster Hall

About ProSciento, Inc.

ProSciento is a metabolism-focused, full scope clinical R&D services provider, with a mission to advance the global development of novel therapeutics for diabetes, NASH and obesity. The company is widely recognized for quality and scientific excellence, an unparalleled methodological toolkit, and extensive experience with virtually all metabolic drug and device classes. Utilizing its scalable R&D services model – combining deep therapeutic area expertise, strategic planning, an unparalleled methodological tool kit, and operational execution from late preclinical to phase III readiness – ProSciento provides highly customizable services for its global client base in today’s rapidly evolving landscape of metabolic drug and device development. For more information, please visit www.prosciento.com.

For media inquiries, please contact:
Abby Devine
Senior Director, Corporate Communications, ProSciento, Inc.
Tel: +1 858 663-6148
abby.devine@prosciento.com

For business development inquires:
bd@prosciento.com

For clinical study enrollment inquires:
Tel: +1 (866) 308-7427
volunteer@prosciento.com